Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

US Legislators Target WuXi Bio and BGI; Aim to Prevent Transfer of US Genomic Data

publication date: Jan 30, 2024

US legislators have proposed a new law called the BIOSECURE act that is designed to protect genomic information about US citizens from Chinese biopharma companies. The legislators want to stop any US medical provider who receives US funds from doing business with BGI, a China sequencing company, and the Wuxi Apptec/WuXi Bio group of CRDMOs. According to the legislators, both of these large China companies have ties to organizations affiliated with the PLA (the People's Liberation Army), Since the announcement of the proposed law, the price of WuXi’s various stock listings have dropped by nearly 30%. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital